Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07424027 · ClinicalTrials.gov registry record · NA

Central Vein Sign in Multiple Sclerosis Extension Study

A NA study of Multiple Sclerosis, sponsored by The Cleveland Clinic.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
3
Study locations

NCT07424027: Recruiting NA study of Multiple Sclerosis, sponsored by The Cleveland Clinic.

NCT07424027 is a NA study of Multiple Sclerosis that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 40 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07424027, a NA study of Multiple Sclerosis, is actively recruiting participants, sponsored by The Cleveland Clinic.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
3
Study locations

Study Summary

Multiple sclerosis (MS) is a common disease of the central nervous system that affects almost 1 million people in the United States. However, diagnosing MS can be difficult and often leads to misdiagnosis. More sensitive and specific biomarkers are needed to help with the diagnosis, prognosis, and evaluation of treatment response for MS. The central vein sign (CVS) and the paramagnetic rim lesion (PRL) are two biomarkers that have shown promise in improving diagnostic accuracy for MS. The goal of this study is to provide pilot information on the long-term performance of the CVS and PRL to help diagnose and follow people with MS. The study will follow 40 participants over 48 months to determine if the CVS and PRL help make a diagnosis of MS and how they can be used to follow people with MS. The study will also examine how PRL and CVS change over 48 months. The results of this pilot study will inform the development of a grant application to extend 5-year follow-up for all 420 participants of the CAVS-MS study. The study will use high-resolution T2\*-weighted MRI to detect the CVS and PRLs. An MRI of the brain with contrast will be used to examine CVS, PRL and longitudinal analysis of lesions that slowly grow over time (slowly expanding lesions \[SELs\]). The results of this study have the potential to improve the accuracy of diagnosing and treating MS.

Primary Outcome

An MRI will be done at the Month 48 visit. Central veins will be counted and lesions will be considered CVS+ using specified criteria. CVS will be determined using Select6, Select3\* by already trained raters from the core CAVS-MS study and using automated lesion analysis.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST MRI Contrast

Study Locations (3)

California

  • Cedars-Sinai Medical Center - Los Angeles

Ohio

  • Cleveland Clinic Foundation - Cleveland

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-10-07
Est. Completion 2027-12-31
Phase NA
The Cleveland Clinic

688 total trials

What NCT07424027 shows while recruiting

NCT07424027 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which MRI Contrast is the first listed.

NCT07424027 reports a single indexed study location in California, Ohio, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07424027 about?

NCT07424027 is a clinical study titled "Central Vein Sign in Multiple Sclerosis Extension Study". Multiple sclerosis (MS) is a common disease of the central nervous system that affects almost 1 million people in the United States. However, diagnosing MS can be difficult and often leads to misdiagnosis. More sensitive and specific biomarkers are needed to help with the diagnosis, prognosis, and e...

What is the current status of trial NCT07424027?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-10-07. Estimated completion is 2027-12-31.

What conditions does trial NCT07424027 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT07424027?

The interventions under investigation include: MRI Contrast (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07424027?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07424027 being conducted?

This trial has 3 study locations across California, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07424027's enrollment target sits among peer trials

40 197th of 315 higher than 108 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07424027, the US trial registry maintained by the National Library of Medicine. NCT07424027 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.